Nucleic Acid-Sensing Pathways During SARS-CoV-2 Infection: Expectations versus Reality

References

• Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis. Methods Mol Biol. 2015;1282:1–23.
   PubMedGoogle Scholar
• Ciotti M, Angeletti S, Minieri M, et al. COVID-19 outbreak: an overview. Chemotherapy. 2019;64(5–6):215–223. doi:10.1159/000507423
   PubMed Web of Science ®Google Scholar
• Zhong NS, Zheng BJ, Li YM, et al. Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People’s Republic of China, in February, 2003. Lancet. 2003;362(9393):1353–1358. doi:10.1016/S0140-6736(03)14630-2
   PubMed Web of Science ®Google Scholar
• Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 2012;367(19):1814–1820. doi:10.1056/NEJMoa1211721
   PubMed Web of Science ®Google Scholar
• Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–733. doi:10.1056/NEJMoa2001017
   PubMed Web of Science ®Google Scholar
• WHO. WHO coronavirus disease (COVID-19) dashboard. Available from: https://covid19.who.int/?gclid=CjwKCAjwx9_4BRAHEiwApAt0ztGCqDKOG3tvC1Gxgs-X7bgQVwEFSi96HD50ZZQUndU-KIrvQa5HmRoCmYgQAvD_BwE. Accessed July 31, 2020.
   Google Scholar
• Bosch BJ, van der Zee R, de Haan CA, Rottier PJ. The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex. J Virol. 2003;77(16):8801–8811.
   PubMed Web of Science ®Google Scholar
• Luk HKH, Li X, Fung J, Lau SKP, Woo PCY. Molecular epidemiology, evolution and phylogeny of SARS coronavirus. Infect Genet Evol. 2019;71:21–30. doi:10.1016/j.meegid.2019.03.001
   PubMed Web of Science ®Google Scholar
• de Wit E, van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol. 2016;14(8):523–534. doi:10.1038/nrmicro.2016.81
   PubMed Web of Science ®Google Scholar
• Brian DA, Baric RS. Coronavirus genome structure and replication. Curr Top Microbiol Immunol. 2005;287:1–30. doi:10.1007/3-540-26765-4_1
   PubMed Web of Science ®Google Scholar
• Li C, Yang Y, Ren L. Genetic evolution analysis of 2019 novel coronavirus and coronavirus from other species. Infect Genet Evol. 2020;82:104285. doi:10.1016/j.meegid.2020.104285
   PubMed Web of Science ®Google Scholar
• Li W, Moore MJ, Vasilieva N, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426(6965):450–454. doi:10.1038/nature02145
   PubMed Web of Science ®Google Scholar
• Qian Z, Travanty EA, Oko L, et al. Innate immune response of human alveolar type II cells infected with severe acute respiratory syndrome-coronavirus. Am J Respir Cell Mol Biol. 2013;48(6):742–748. doi:10.1165/rcmb.2012-0339OC
   PubMed Web of Science ®Google Scholar
• Raj VS, Mou H, Smits SL, et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature. 2013;495(7440):251–254. doi:10.1038/nature12005
   PubMed Web of Science ®Google Scholar
• Lu G, Hu Y, Wang Q, et al. Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26. Nature. 2013;500(7461):227–231. doi:10.1038/nature12328
   PubMed Web of Science ®Google Scholar
• Choudhury A, Mukherjee S. In silico studies on the comparative characterization of the interactions of SARS-CoV-2 spike glycoprotein with ACE-2 receptor homologs and human TLRs. J Med Virol. 2020;92(10):2105–2113. doi:10.1002/jmv.25987
   PubMed Web of Science ®Google Scholar
• Neuman BW, Kiss G, Kunding AH, et al. A structural analysis of M protein in coronavirus assembly and morphology. J Struct Biol. 2011;174(1):11–22. doi:10.1016/j.jsb.2010.11.021
   PubMed Web of Science ®Google Scholar
• Kindler E, Thiel V, Weber F. Interaction of SARS and MERS coronaviruses with the antiviral interferon response. Adv Virus Res. 2016;96:219–243.
   PubMed Web of Science ®Google Scholar
• Li G, Fan Y, Lai Y, et al. Coronavirus infections and immune responses. J Med Virol. 2020;92(4):424–432. doi:10.1002/jmv.25685
   PubMed Web of Science ®Google Scholar
• Jensen S, Thomsen AR. Sensing of RNA viruses: a review of innate immune receptors involved in recognizing RNA virus invasion. J Virol. 2012;86(6):2900–2910. doi:10.1128/JVI.05738-11
   PubMed Web of Science ®Google Scholar
• Barber GN. Cytoplasmic DNA innate immune pathways. Immunol Rev. 2011;243(1):99–108. doi:10.1111/j.1600-065X.2011.01051.x
   PubMed Web of Science ®Google Scholar
• Tan X, Sun L, Chen J, Chen ZJ. Detection of microbial infections through innate immune sensing of nucleic acids. Annu Rev Microbiol. 2018;72(1):447–478. doi:10.1146/annurev-micro-102215-095605
   PubMed Web of Science ®Google Scholar
• Schneider WM, Chevillotte MD, Rice CM. Interferon-stimulated genes: a complex web of host defenses. Annu Rev Immunol. 2014;32(1):513–545. doi:10.1146/annurev-immunol-032713-120231
   PubMed Web of Science ®Google Scholar
• Kell AM, Gale M Jr. RIG-I in RNA virus recognition. Virology. 2015;479–480:110–121. doi:10.1016/j.virol.2015.02.017
   PubMed Web of Science ®Google Scholar
• Yoneyama M, Fujita T. RNA recognition and signal transduction by RIG-I-like receptors. Immunol Rev. 2009;227(1):54–65. doi:10.1111/j.1600-065X.2008.00727.x
   PubMed Web of Science ®Google Scholar
• Binder M, Eberle F, Seitz S, et al. Molecular mechanism of signal perception and integration by the innate immune sensor retinoic acid-inducible gene-I (RIG-I). J Biol Chem. 2011;286(31):27278–27287. doi:10.1074/jbc.M111.256974
   PubMed Web of Science ®Google Scholar
• Goubau D, Schlee M, Deddouche S, et al. Antiviral immunity via RIG-I-mediated recognition of RNA bearing 5ʹ-diphosphates. Nature. 2014;514(7522):372–375. doi:10.1038/nature13590
   PubMed Web of Science ®Google Scholar
• Pichlmair A, Schulz O, Tan CP, et al. Activation of MDA5 requires higher-order RNA structures generated during virus infection. J Virol. 2009;83(20):10761–10769. doi:10.1128/JVI.00770-09
   PubMed Web of Science ®Google Scholar
• Takeuchi O, Akira S. MDA5/RIG-I and virus recognition. Curr Opin Immunol. 2008;20(1):17–22. doi:10.1016/j.coi.2008.01.002
   PubMed Web of Science ®Google Scholar
• Belgnaoui SM, Paz S, Hiscott J. Orchestrating the interferon antiviral response through the mitochondrial antiviral signaling (MAVS) adapter. Curr Opin Immunol. 2011;23(5):564–572. doi:10.1016/j.coi.2011.08.001
   PubMed Web of Science ®Google Scholar
• Liu S, Chen J, Cai X, et al. MAVS recruits multiple ubiquitin E3 ligases to activate antiviral signaling cascades. Elife. 2013;2:e00785. doi:10.7554/eLife.00785
   PubMed Web of Science ®Google Scholar
• Yoshikawa T, Hill TE, Yoshikawa N, et al. Dynamic innate immune responses of human bronchial epithelial cells to severe acute respiratory syndrome-associated coronavirus infection. PLoS One. 2010;5(1):e8729. doi:10.1371/journal.pone.0008729
   PubMed Web of Science ®Google Scholar
• Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell. 2006;124(4):783–801. doi:10.1016/j.cell.2006.02.015
   PubMed Web of Science ®Google Scholar
• Fitzgerald KA, Kagan JC. Toll-like receptors and the control of immunity. Cell. 2020;180(6):1044–1066. doi:10.1016/j.cell.2020.02.041
   PubMed Web of Science ®Google Scholar
• Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on toll-like receptors. Nat Immunol. 2010;11(5):373–384. doi:10.1038/ni.1863
   PubMed Web of Science ®Google Scholar
• Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by toll-like receptor 3. Nature. 2001;413(6857):732–738. doi:10.1038/35099560
   PubMed Web of Science ®Google Scholar
• Totura AL, Whitmore A, Agnihothram S, et al. Toll-like receptor 3 signaling via TRIF contributes to a protective innate immune response to severe acute respiratory syndrome coronavirus infection. mBio. 2015;6(3):e00638–15. doi:10.1128/mBio.00638-15
   PubMed Web of Science ®Google Scholar
• Zhao J, Li K, Wohlford-Lenane C, et al. Rapid generation of a mouse model for Middle East respiratory syndrome. Proc Natl Acad Sci U S A. 2014;111(13):4970–4975. doi:10.1073/pnas.1323279111
   PubMed Web of Science ®Google Scholar
• Cervantes-Barragan L, Zust R, Weber F, et al. Control of coronavirus infection through plasmacytoid dendritic-cell-derived type I interferon. Blood. 2007;109(3):1131–1137. doi:10.1182/blood-2006-05-023770
   PubMed Web of Science ®Google Scholar
• van der Made CI, Simons A, Schuurs-Hoeijmakers J, et al. Presence of genetic variants among young men with severe COVID-19. JAMA. 2020;324(7):663. doi:10.1001/jama.2020.13719
   PubMed Web of Science ®Google Scholar
• Sheahan T, Morrison TE, Funkhouser W, et al. MyD88 is required for protection from lethal infection with a mouse-adapted SARS-CoV. PLoS Pathog. 2008;4(12):e1000240. doi:10.1371/journal.ppat.1000240
   PubMed Web of Science ®Google Scholar
• Swanson KV, Deng M, Ting JP. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nat Rev Immunol. 2019;19(8):477–489. doi:10.1038/s41577-019-0165-0
   PubMed Web of Science ®Google Scholar
• Zhao C, Zhao W. NLRP3 inflammasome-a key player in antiviral responses. Front Immunol. 2020;11:211. doi:10.3389/fimmu.2020.00211
   PubMed Web of Science ®Google Scholar
• Chan JF, Kok KH, Zhu Z, et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect. 2020;9(1):221–236. doi:10.1128/JVI.77.16.8801-8811.2003
   PubMed Web of Science ®Google Scholar
• Grifoni A, Sidney J, Zhang Y, Scheuermann RH, Peters B, Sette A. A sequence homology and bioinformatic approach can predict candidate targets for immune responses to SARS-CoV-2. Cell Host Microbe. 2020;27(4):671–80e2. doi:10.1016/j.chom.2020.03.002
   PubMed Web of Science ®Google Scholar
• Xu J, Zhao S, Teng T, et al. Systematic comparison of two animal-to-human transmitted human coronaviruses: SARS-CoV-2 and SARS-CoV. Viruses. 2020;12(2):244. doi:10.3390/v12020244
   PubMed Web of Science ®Google Scholar
• Nieto-Torres JL, DeDiego ML, Verdia-Baguena C, et al. Severe acute respiratory syndrome coronavirus envelope protein ion channel activity promotes virus fitness and pathogenesis. PLoS Pathog. 2014;10(5):e1004077. doi:10.1371/journal.ppat.1004077
   PubMed Web of Science ®Google Scholar
• Nieto-Torres JL, Verdia-Baguena C, Jimenez-Guardeno JM, et al. Severe acute respiratory syndrome coronavirus E protein transports calcium ions and activates the NLRP3 inflammasome. Virology. 2015;485:330–339. doi:10.1016/j.virol.2015.08.010
   PubMed Web of Science ®Google Scholar
• Chen IY, Moriyama M, Chang MF, Ichinohe T. Severe acute respiratory syndrome coronavirus viroporin 3a activates the NLRP3 inflammasome. Front Microbiol. 2019;10:50. doi:10.3389/fmicb.2019.00050
   PubMed Web of Science ®Google Scholar
• Zhou R, Yazdi AS, Menu P, Tschopp J. A role for mitochondria in NLRP3 inflammasome activation. Nature. 2011;469(7329):221–225. doi:10.1038/nature09663
   PubMed Web of Science ®Google Scholar
• Siu KL, Yuen KS, Castano-Rodriguez C, et al. Severe acute respiratory syndrome coronavirus ORF3a protein activates the NLRP3 inflammasome by promoting TRAF3-dependent ubiquitination of ASC. FASEB J. 2019;33(8):8865–8877. doi:10.1096/fj.201802418R
   PubMed Web of Science ®Google Scholar
• Yue Y, Nabar NR, Shi CS, et al. SARS-coronavirus open reading frame-3a drives multimodal necrotic cell death. Cell Death Dis. 2018;9(9):904. doi:10.1038/s41419-018-0917-y
   PubMedGoogle Scholar
• He Y, Hara H, Nunez G. Mechanism and regulation of NLRP3 inflammasome activation. Trends Biochem Sci. 2016;41(12):1012–1021. doi:10.1016/j.tibs.2016.09.002
   PubMed Web of Science ®Google Scholar
• Shi CS, Nabar NR, Huang NN, Kehrl JH. SARS-coronavirus open reading frame-8b triggers intracellular stress pathways and activates NLRP3 inflammasomes. Cell Death Discov. 2019;5(1):101. doi:10.1038/s41420-019-0181-7
   PubMedGoogle Scholar
• Neuman BW, Joseph JS, Saikatendu KS, et al. Proteomics analysis unravels the functional repertoire of coronavirus nonstructural protein 3. J Virol. 2008;82(11):5279–5294. doi:10.1128/JVI.02631-07
   PubMed Web of Science ®Google Scholar
• Wu C, Liu Y, Yang Y, et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm Sin B. 2020;10(5):766–788. doi:10.1016/j.apsb.2020.02.008
   PubMed Web of Science ®Google Scholar
• Chang YS, Ko BH, Ju JC, et al. (SUD) of severe acute respiratory syndrome coronavirus induces NLRP3 inflammasome-dependent CXCL10-mediated pulmonary inflammation. Int J Mol Sci. 2020;21:9.
   Web of Science ®Google Scholar
• Jiang Y, Li J, Teng Y, et al. Complement receptor C5aR1 inhibition reduces pyroptosis in hDPP4-transgenic mice infected with MERS-CoV. Viruses. 2019;11(1):39. doi:10.3390/v11010039
   PubMed Web of Science ®Google Scholar
• Jiang Y, Zhao G, Song N, et al. Blockade of the C5a-C5aR axis alleviates lung damage in hDPP4-transgenic mice infected with MERS-CoV. Emerg Microbes Infect. 2018;7(1):77. doi:10.1038/s41426-018-0063-8
   PubMed Web of Science ®Google Scholar
• Barber GN. STING: infection, inflammation and cancer. Nat Rev Immunol. 2015;15(12):760–770. doi:10.1038/nri3921
   PubMed Web of Science ®Google Scholar
• Lee J, Ghonime MG, Wang R, Cassady KA. The antiviral apparatus: STING and oncolytic virus restriction. Mol Ther Oncolytics. 2019;13:7–13. doi:10.1016/j.omto.2019.02.002
   PubMed Web of Science ®Google Scholar
• Sun B, Sundstrom KB, Chew JJ, et al. Dengue virus activates cGAS through the release of mitochondrial DNA. Sci Rep. 2017;7(1):3594. doi:10.1038/s41598-017-03932-1
   PubMedGoogle Scholar
• Zevini A, Olagnier D, Hiscott J. Crosstalk between cytoplasmic RIG-I and STING sensing pathways. Trends Immunol. 2017;38(3):194–205. doi:10.1016/j.it.2016.12.004
   PubMed Web of Science ®Google Scholar
• Franz KM, Neidermyer WJ, Tan YJ, Whelan SPJ, Kagan JC. STING-dependent translation inhibition restricts RNA virus replication. Proc Natl Acad Sci U S A. 2018;115(9):E2058–E67. doi:10.1073/pnas.1716937115
   PubMed Web of Science ®Google Scholar
• Rose KM, Elliott R, Martinez-Sobrido L, Garcia-Sastre A, Weiss SR. Murine coronavirus delays expression of a subset of interferon-stimulated genes. J Virol. 2010;84(11):5656–5669. doi:10.1128/JVI.00211-10
   PubMed Web of Science ®Google Scholar
• Menachery VD, Eisfeld AJ, Schafer A, et al. Pathogenic influenza viruses and coronaviruses utilize similar and contrasting approaches to control interferon-stimulated gene responses. mBio. 2014;5(3):e01174–14.
   PubMed Web of Science ®Google Scholar
• Blanco-Melo D, Nilsson-Payant BE, Liu WC, et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell. 2020;181(5):1036–45e9.
   PubMed Web of Science ®Google Scholar
• Wu F, Wang A, Liu M, Wang Q, Chen J, Xia S, et al. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. medRxiv. 2020. doi:10.1101/2020.03.30.20047365
   Google Scholar
• Snijder EJ, van der Meer Y, Zevenhoven-Dobbe J, et al. Ultrastructure and origin of membrane vesicles associated with the severe acute respiratory syndrome coronavirus replication complex. J Virol. 2006;80(12):5927–5940.
   PubMed Web of Science ®Google Scholar
• Knoops K, Kikkert M, Worm SH, et al. SARS-coronavirus replication is supported by a reticulovesicular network of modified endoplasmic reticulum. PLoS Biol. 2008;6(9):e226. doi:10.1371/journal.pbio.0060226
   PubMed Web of Science ®Google Scholar
• Deng X, Hackbart M, Mettelman RC, et al. Coronavirus nonstructural protein 15 mediates evasion of dsRNA sensors and limits apoptosis in macrophages. Proc Natl Acad Sci U S A. 2017;114(21):E4251–E60. doi:10.1073/pnas.1618310114
   PubMed Web of Science ®Google Scholar
• Cameron MJ, Kelvin AA, Leon AJ, et al. Lack of innate interferon responses during SARS coronavirus infection in a vaccination and reinfection ferret model. PLoS One. 2012;7(9):e45842. doi:10.1371/journal.pone.0045842
   PubMed Web of Science ®Google Scholar
• Minakshi R, Padhan K, Rani M, Khan N, Ahmad F, Jameel S. The SARS Coronavirus 3a protein causes endoplasmic reticulum stress and induces ligand-independent downregulation of the type 1 interferon receptor. PLoS One. 2009;4(12):e8342. doi:10.1371/journal.pone.0008342
   PubMed Web of Science ®Google Scholar
• Siu KL, Kok KH, Ng MH, et al. Severe acute respiratory syndrome coronavirus M protein inhibits type I interferon production by impeding the formation of TRAF3.TANK.TBK1/IKKepsilon complex. J Biol Chem. 2009;284(24):16202–16209. doi:10.1074/jbc.M109.008227
   PubMed Web of Science ®Google Scholar
• Wathelet MG, Orr M, Frieman MB, Baric RS. Severe acute respiratory syndrome coronavirus evades antiviral signaling: role of nsp1 and rational design of an attenuated strain. J Virol. 2007;81(21):11620–11633. doi:10.1128/JVI.00702-07
   PubMed Web of Science ®Google Scholar
• Huang C, Lokugamage KG, Rozovics JM, Narayanan K, Semler BL, Makino S. SARS coronavirus nsp1 protein induces template-dependent endonucleolytic cleavage of mRNAs: viral mRNAs are resistant to nsp1-induced RNA cleavage. PLoS Pathog. 2011;7(12):e1002433. doi:10.1371/journal.ppat.1002433
   PubMed Web of Science ®Google Scholar
• Kamitani W, Huang C, Narayanan K, Lokugamage KG, Makino S. A two-pronged strategy to suppress host protein synthesis by SARS coronavirus Nsp1 protein. Nat Struct Mol Biol. 2009;16(11):1134–1140. doi:10.1038/nsmb.1680
   PubMed Web of Science ®Google Scholar
• Kamitani W, Narayanan K, Huang C, et al. Severe acute respiratory syndrome coronavirus nsp1 protein suppresses host gene expression by promoting host mRNA degradation. Proc Natl Acad Sci U S A. 2006;103(34):12885–12890. doi:10.1073/pnas.0603144103
   PubMed Web of Science ®Google Scholar
• Lokugamage KG, Narayanan K, Huang C, Makino S. Severe acute respiratory syndrome coronavirus protein nsp1 is a novel eukaryotic translation inhibitor that represses multiple steps of translation initiation. J Virol. 2012;86(24):13598–13608. doi:10.1128/JVI.01958-12
   PubMed Web of Science ®Google Scholar
• Narayanan K, Huang C, Lokugamage K, et al. Severe acute respiratory syndrome coronavirus nsp1 suppresses host gene expression, including that of type I interferon, in infected cells. J Virol. 2008;82(9):4471–4479. doi:10.1128/JVI.02472-07
   PubMed Web of Science ®Google Scholar
• Tanaka T, Kamitani W, DeDiego ML, Enjuanes L, Matsuura Y. Severe acute respiratory syndrome coronavirus nsp1 facilitates efficient propagation in cells through a specific translational shutoff of host mRNA. J Virol. 2012;86(20):11128–11137. doi:10.1128/JVI.01700-12
   PubMed Web of Science ®Google Scholar
• Clementz MA, Chen Z, Banach BS, et al. Deubiquitinating and interferon antagonism activities of coronavirus papain-like proteases. J Virol. 2010;84(9):4619–4629. doi:10.1128/JVI.02406-09
   PubMed Web of Science ®Google Scholar
• Devaraj SG, Wang N, Chen Z, et al. Regulation of IRF-3-dependent innate immunity by the papain-like protease domain of the severe acute respiratory syndrome coronavirus. J Biol Chem. 2007;282(44):32208–32221. doi:10.1074/jbc.M704870200
   PubMed Web of Science ®Google Scholar
• Matthews K, Schafer A, Pham A, Frieman M. The SARS coronavirus papain like protease can inhibit IRF3 at a post activation step that requires deubiquitination activity. Virol J. 2014;11(1):209. doi:10.1186/s12985-014-0209-9
   PubMed Web of Science ®Google Scholar
• Frieman M, Ratia K, Johnston RE, Mesecar AD, Baric RS. Severe acute respiratory syndrome coronavirus papain-like protease ubiquitin-like domain and catalytic domain regulate antagonism of IRF3 and NF-kappaB signaling. J Virol. 2009;83(13):6689–6705. doi:10.1128/JVI.02220-08
   PubMed Web of Science ®Google Scholar
• Chen X, Yang X, Zheng Y, Yang Y, Xing Y, Chen Z. SARS coronavirus papain-like protease inhibits the type I interferon signaling pathway through interaction with the STING-TRAF3-TBK1 complex. Protein Cell. 2014;5(5):369–381. doi:10.1007/s13238-014-0026-3
   PubMed Web of Science ®Google Scholar
• Sun L, Xing Y, Chen X, et al. Coronavirus papain-like proteases negatively regulate antiviral innate immune response through disruption of STING-mediated signaling. PLoS One. 2012;7(2):e30802. doi:10.1371/journal.pone.0030802
   PubMed Web of Science ®Google Scholar
• Yang X, Chen X, Bian G, et al. Proteolytic processing, deubiquitinase and interferon antagonist activities of Middle East respiratory syndrome coronavirus papain-like protease. J Gen Virol. 2014;95(Pt 3):614–626. doi:10.1099/vir.0.059014-0
   PubMed Web of Science ®Google Scholar
• Yuen CK, Lam JY, Wong WM, et al. SARS-CoV-2 nsp13, nsp14, nsp15 and orf6 function as potent interferon antagonists. Emerg Microbes Infect. 2020;9(1):1418–1428. doi:10.1080/22221751.2020.1780953
   PubMed Web of Science ®Google Scholar
• Deng X, Baker SC. An “old” protein with a new story: coronavirus endoribonuclease is important for evading host antiviral defenses. Virology. 2018;517:157–163. doi:10.1016/j.virol.2017.12.024
   PubMed Web of Science ®Google Scholar
• Deng X, van Geelen A, Buckley AC, et al. Coronavirus endoribonuclease activity in porcine epidemic diarrhea virus suppresses type i and type III interferon responses. J Virol. 2019;93(8):8. doi:10.1128/JVI.02000-18
   Web of Science ®Google Scholar
• Hackbart M, Deng X, Baker SC. Coronavirus endoribonuclease targets viral polyuridine sequences to evade activating host sensors. Proc Natl Acad Sci U S A. 2020;117(14):8094–8103. doi:10.1073/pnas.1921485117
   PubMed Web of Science ®Google Scholar
• Zust R, Cervantes-Barragan L, Habjan M, et al. Ribose 2ʹ-O-methylation provides a molecular signature for the distinction of self and non-self mRNA dependent on the RNA sensor Mda5. Nat Immunol. 2011;12(2):137–143. doi:10.1038/ni.1979
   PubMed Web of Science ®Google Scholar
• Kopecky-Bromberg SA, Martinez-Sobrido L, Frieman M, Baric RA, Palese P. Severe acute respiratory syndrome coronavirus open reading frame (ORF) 3b, ORF 6, and nucleocapsid proteins function as interferon antagonists. J Virol. 2007;81(2):548–557. doi:10.1128/JVI.01782-06
   PubMed Web of Science ®Google Scholar
• Konno Y, Kimura I, Uriu K, et al. SARS-CoV-2 ORF3b is a potent interferon antagonist whose activity is further increased by a naturally occurring elongation variant. bioRxiv. 2020;2020.05.11.088179.
   Google Scholar
• Frieman M, Yount B, Heise M, Kopecky-Bromberg SA, Palese P, Baric RS. Severe acute respiratory syndrome coronavirus ORF6 antagonizes STAT1 function by sequestering nuclear import factors on the rough endoplasmic reticulum/Golgi membrane. J Virol. 2007;81(18):9812–9824. doi:10.1128/JVI.01012-07
   PubMed Web of Science ®Google Scholar
• Wong HH, Fung TS, Fang S, Huang M, Le MT, Liu DX. Accessory proteins 8b and 8ab of severe acute respiratory syndrome coronavirus suppress the interferon signaling pathway by mediating ubiquitin-dependent rapid degradation of interferon regulatory factor 3. Virology. 2018;515:165–175. doi:10.1016/j.virol.2017.12.028
   PubMed Web of Science ®Google Scholar
• Shi CS, Qi HY, Boularan C, et al. SARS-coronavirus open reading frame-9b suppresses innate immunity by targeting mitochondria and the MAVS/TRAF3/TRAF6 signalosome. J Immunol. 2014;193(6):3080–3089. doi:10.4049/jimmunol.1303196
   PubMed Web of Science ®Google Scholar
• Lokugamage KG, Hage A, Schindewolf C, Rajsbaum R. SARS-CoV-2 is sensitive to type I interferon pretreatment. bioRxiv. 2020.
   Google Scholar
• Lu X, Pan J, Tao J, Guo D. SARS-CoV nucleocapsid protein antagonizes IFN-beta response by targeting initial step of IFN-beta induction pathway, and its C-terminal region is critical for the antagonism. Virus Genes. 2011;42(1):37–45. doi:10.1007/s11262-010-0544-x
   PubMed Web of Science ®Google Scholar
• Hu Y, Li W, Gao T, et al. The severe acute respiratory syndrome coronavirus nucleocapsid inhibits type i interferon production by interfering with TRIM25-mediated RIG-I ubiquitination. J Virol. 2017;91(8):8. doi:10.1128/JVI.02143-16
   Web of Science ®Google Scholar
• Hadjadj J, Yatim N, Barnabei L, et al. Impaired type I interferon activity and exacerbated inflammatory responses in severe Covid-19 patients. medRxiv. 2020;2020.04.19.20068015.
   Google Scholar
• Ivashkiv LB, Donlin LT. Regulation of type I interferon responses. Nat Rev Immunol. 2014;14(1):36–49. doi:10.1038/nri3581
   PubMed Web of Science ®Google Scholar
• Channappanavar R, Fehr AR, Vijay R, et al. Dysregulated type i interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice. Cell Host Microbe. 2016;19(2):181–193. doi:10.1016/j.chom.2016.01.007
   PubMed Web of Science ®Google Scholar
• Channappanavar R, Fehr AR, Zheng J, et al. IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes. J Clin Invest. 2019;129(9):3625–3639. doi:10.1172/JCI126363
   PubMed Web of Science ®Google Scholar
• Mantlo E, Bukreyeva N, Maruyama J, Paessler S, Huang C. Antiviral activities of type I interferons to SARS-CoV-2 infection. Antiviral Res. 2020;179:104811. doi:10.1016/j.antiviral.2020.104811
   PubMed Web of Science ®Google Scholar
• Stanifer ML, Kee C, Cortese M. et al. Critical role of type III interferon in controlling SARS-CoV-2 infection, replication and spread in primary human intestinal epithelial cells. bioRxiv. 2020;2020.04.24.059667. doi:10.1101/2020.07.19.210955
   PubMedGoogle Scholar
• Pfaender S, Mar KB, Michailidis E. et al. LY6E impairs coronavirus fusion and confers immune control of viral disease. bioRxiv. 2020;2020.03.05.979260. doi:10.1101/2020.03.05.979260
   PubMedGoogle Scholar
• Huang IC, Bailey CC, Weyer JL, et al. Distinct patterns of IFITM-mediated restriction of filoviruses, SARS coronavirus, and influenza A virus. PLoS Pathog. 2011;7(1):e1001258. doi:10.1371/journal.ppat.1001258
   PubMed Web of Science ®Google Scholar
• Zhao X, Guo F, Liu F, et al. Interferon induction of IFITM proteins promotes infection by human coronavirus OC43. Proc Natl Acad Sci U S A. 2014;111(18):6756–6761. doi:10.1073/pnas.1320856111
   PubMed Web of Science ®Google Scholar
• Zhao X, Sehgal M, Hou Z, et al. Identification of residues controlling restriction versus enhancing activities of IFITM proteins on entry of human coronaviruses. J Virol. 2018;92:6.
   Web of Science ®Google Scholar
• Rockx B, Baas T, Zornetzer GA, et al. Early upregulation of acute respiratory distress syndrome-associated cytokines promotes lethal disease in an aged-mouse model of severe acute respiratory syndrome coronavirus infection. J Virol. 2009;83(14):7062–7074. doi:10.1128/JVI.00127-09
   PubMed Web of Science ®Google Scholar
• Huang KJ, Su IJ, Theron M, et al. An interferon-gamma-related cytokine storm in SARS patients. J Med Virol. 2005;75(2):185–194. doi:10.1002/jmv.20255
   PubMed Web of Science ®Google Scholar
• Haagmans BL, Kuiken T, Martina BE, et al. Pegylated interferon-alpha protects type 1 pneumocytes against SARS coronavirus infection in macaques. Nat Med. 2004;10(3):290–293. doi:10.1038/nm1001
   PubMed Web of Science ®Google Scholar
• Tan EL, Ooi EE, Lin CY, Tan HC, Ling AE, Lim B. Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs. Emerg Infect Dis. 2004;10(4):581–586. doi:10.3201/eid1004.030458
   PubMed Web of Science ®Google Scholar
• Toldo S, Abbate A. The NLRP3 inflammasome in acute myocardial infarction. Nat Rev Cardiol. 2018;15(4):203–214. doi:10.1038/nrcardio.2017.161
   PubMed Web of Science ®Google Scholar
• Misawa T, Takahama M, Kozaki T, et al. Microtubule-driven spatial arrangement of mitochondria promotes activation of the NLRP3 inflammasome. Nat Immunol. 2013;14(5):454–460. doi:10.1038/ni.2550
   PubMed Web of Science ®Google Scholar
• Marques-da-Silva C, Chaves MM, Castro NG, Coutinho-Silva R, Guimaraes MZ. Colchicine inhibits cationic dye uptake induced by ATP in P2X2 and P2X7 receptor-expressing cells: implications for its therapeutic action. Br J Pharmacol. 2011;163(5):912–926. doi:10.1111/j.1476-5381.2011.01254.x
   PubMed Web of Science ®Google Scholar
• Deftereos SG, Siasos G, Giannopoulos G, et al. The Greek study in the effects of colchicine in Covid-19 complications prevention (GRECCO-19 study): rationale and study design. Hellenic J Cardiol. 2020;61(1):42–45. doi:10.1016/j.hjc.2020.03.002
   PubMed Web of Science ®Google Scholar
• Deftereos SG, Giannopoulos G, Vrachatis DA, et al. Effect of colchicine vs standard care on cardiac and inflammatory biomarkers and clinical outcomes in patients hospitalized with coronavirus disease 2019: the GRECCO-19 randomized clinical trial. JAMA Netw Open. 2020;3(6):e2013136. doi:10.1001/jamanetworkopen.2020.13136
   PubMed Web of Science ®Google Scholar
• Chen X, Wang N, Zhu Y, Lu Y, Liu X, Zheng J. The antimalarial chloroquine suppresses LPS-induced NLRP3 inflammasome activation and confers protection against murine endotoxic shock. Mediators Inflamm. 2017;2017:6543237. doi:10.1155/2017/6543237
   PubMed Web of Science ®Google Scholar
• Vincent MJ, Bergeron E, Benjannet S, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005;2(1):69. doi:10.1186/1743-422X-2-69
   PubMed Web of Science ®Google Scholar
• Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020;71(15):732–739. doi:10.1093/cid/ciaa237
   PubMed Web of Science ®Google Scholar
• Jp K. NIH halts clinical trial of hydroxychloroquine. Available from: https://www.nih.gov/news-events/news-releases/nih-halts-clinical-trial-hydroxychloroquine. 2020. Accessed July 31, 2020.
   Google Scholar
• Lucchesi A, Silimbani P, Musuraca G, et al. Clinical and biological data on the use of hydroxychloroquine against SARS-CoV-2 could support the role of the NLRP3 inflammasome in the pathogenesis of respiratory disease. J Med Virol. 2020. doi:10.1002/jmv.26217
   PubMed Web of Science ®Google Scholar
• Coll RC, Robertson AA, Chae JJ, et al. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat Med. 2015;21(3):248–255. doi:10.1038/nm.3806
   PubMed Web of Science ®Google Scholar
• Marchetti C, Swartzwelter B, Gamboni F, et al. OLT1177, a beta-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation. Proc Natl Acad Sci U S A. 2018;115(7):E1530–E9. doi:10.1073/pnas.1716095115
   PubMed Web of Science ®Google Scholar
• Freeman TL, Swartz TH. Targeting the NLRP3 inflammasome in severe COVID-19. Front Immunol. 2020;11:1518. doi:10.3389/fimmu.2020.01518
   PubMed Web of Science ®Google Scholar
• Ucciferri C, Auricchio A, Di Nicola M, et al. Canakinumab in a subgroup of patients with COVID-19. Lancet Rheumatol. 2020;2(8):e457–ee8. doi:10.1016/S2665-9913(20)30167-3
   PubMedGoogle Scholar
• Rajasekaran S, Kruse K, Kovey K, et al. Therapeutic role of anakinra, an interleukin-1 receptor antagonist, in the management of secondary hemophagocytic lymphohistiocytosis/sepsis/multiple organ dysfunction/macrophage activating syndrome in critically ill children. Pediatr Crit Care Med. 2014;15(5):401–408. doi:10.1097/PCC.0000000000000078
   PubMed Web of Science ®Google Scholar
• Shakoory B, Carcillo JA, Chatham WW, et al. Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior phase III trial. Crit Care Med. 2016;44(2):275–281. doi:10.1097/CCM.0000000000001402
   PubMed Web of Science ®Google Scholar
• Lind-Holst M, Hartling UB, Christensen AE. High-dose anakinra as treatment for macrophage activation syndrome caused by refractory Kawasaki disease in an infant. BMJ Case Rep. 2019;12(8):8. doi:10.1136/bcr-2019-229708
   Google Scholar
• Lazear HM, Schoggins JW, Diamond MS. Shared and distinct functions of type I and type III interferons. Immunity. 2019;50(4):907–923. doi:10.1016/j.immuni.2019.03.025
   PubMed Web of Science ®Google Scholar
• Cinatl J, Morgenstern B, Bauer G, Chandra P, Rabenau H, Doerr HW. Treatment of SARS with human interferons. Lancet. 2003;362(9380):293–294. doi:10.1016/S0140-6736(03)13973-6
   PubMed Web of Science ®Google Scholar
• Spiegel M, Pichlmair A, Muhlberger E, Haller O, Weber F. The antiviral effect of interferon-beta against SARS-coronavirus is not mediated by MxA protein. J Clin Virol. 2004;30(3):211–213. doi:10.1016/j.jcv.2003.11.013
   PubMed Web of Science ®Google Scholar
• Morgenstern B, Michaelis M, Baer PC, Doerr HW, Cinatl J Jr. Ribavirin and interferon-beta synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines. Biochem Biophys Res Commun. 2005;326(4):905–908. doi:10.1016/j.bbrc.2004.11.128
   PubMed Web of Science ®Google Scholar
• Stroher U, DiCaro A, Li Y, et al. Severe acute respiratory syndrome-related coronavirus is inhibited by interferon-alpha. J Infect Dis. 2004;189(7):1164–1167. doi:10.1086/382597
   PubMed Web of Science ®Google Scholar
• Loutfy MR, Blatt LM, Siminovitch KA, et al. Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. JAMA. 2003;290(24):3222–3228. doi:10.1001/jama.290.24.3222
   PubMed Web of Science ®Google Scholar
• Zielecki F, Weber M, Eickmann M, et al. Human cell tropism and innate immune system interactions of human respiratory coronavirus EMC compared to those of severe acute respiratory syndrome coronavirus. J Virol. 2013;87(9):5300–5304. doi:10.1128/JVI.03496-12
   PubMed Web of Science ®Google Scholar
• Hart BJ, Dyall J, Postnikova E, et al. Interferon-beta and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays. J Gen Virol. 2014;95(Pt 3):571–577. doi:10.1099/vir.0.061911-0
   PubMedGoogle Scholar
• de Wilde AH, Raj VS, Oudshoorn D, et al. MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-alpha treatment. J Gen Virol. 2013;94(Pt 8):1749–1760. doi:10.1099/vir.0.052910-0
   PubMedGoogle Scholar
• Chan JF, Yao Y, Yeung ML, et al. Treatment with lopinavir/ritonavir or interferon-beta1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset. J Infect Dis. 2015;212(12):1904–1913. doi:10.1093/infdis/jiv392
   PubMed Web of Science ®Google Scholar
• Falzarano D, de Wit E, Rasmussen AL, et al. Treatment with interferon-alpha2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. Nat Med. 2013;19(10):1313–1317. doi:10.1038/nm.3362
   PubMed Web of Science ®Google Scholar
• Omrani AS, Saad MM, Baig K, et al. Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study. Lancet Infect Dis. 2014;14(11):1090–1095. doi:10.1016/S1473-3099(14)70920-X
   PubMed Web of Science ®Google Scholar
• Al-Tawfiq JA, Momattin H, Dib J, Memish ZA. Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study. Int J Infect Dis. 2014;20:42–46. doi:10.1016/j.ijid.2013.12.003
   PubMed Web of Science ®Google Scholar
• Sallard E, Lescure FX, Yazdanpanah Y, Mentre F, Peiffer-Smadja N. Type 1 interferons as a potential treatment against COVID-19. Antiviral Res. 2020;178:104791. doi:10.1016/j.antiviral.2020.104791
   PubMed Web of Science ®Google Scholar
• Zhou Q, Wei X-S, Xiang X, et al. Interferon-a2b treatment for COVID-19. medRxiv. 2020;2020.04.06.20042580.
   Google Scholar
• Hung IF, Lung KC, Tso EY, et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, Phase 2 trial. Lancet. 2020;395(10238):1695–1704. doi:10.1016/S0140-6736(20)31042-4
   PubMed Web of Science ®Google Scholar
• Shalhoub S. Interferon beta-1b for COVID-19. Lancet. 2020;395(10238):1670–1671. doi:10.1016/S0140-6736(20)31101-6
   PubMed Web of Science ®Google Scholar
• Irvani SSN, Golmohammadi M, Pourhoseingholi MA, Shokouhi S, Darazam IA. Effectiveness of interferon beta 1a, compared to interferon beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trial. Trials. 2020;21(1):473. doi:10.1186/s13063-020-04382-3
   PubMed Web of Science ®Google Scholar
• Acharya D, Liu G, Gack MU. Dysregulation of type I interferon responses in COVID-19. Nat Rev Immunol. 2020;20(7):397–398. doi:10.1038/s41577-020-0346-x
   PubMed Web of Science ®Google Scholar
• Mordstein M, Neugebauer E, Ditt V, et al. Lambda interferon renders epithelial cells of the respiratory and gastrointestinal tracts resistant to viral infections. J Virol. 2010;84(11):5670–5677. doi:10.1128/JVI.00272-10
   PubMed Web of Science ®Google Scholar
• Jeon YJ, Gil CH, Jo A, Won J, Kim S, Kim HJ. The influence of interferon-lambda on restricting Middle East respiratory syndrome coronavirus replication in the respiratory epithelium. Antiviral Res. 2020;180:104860. doi:10.1016/j.antiviral.2020.104860
   PubMed Web of Science ®Google Scholar
• Dinnon KH, Leist SR, Schäfer A, et al. A mouse-adapted SARS-CoV-2 model for the evaluation of COVID-19 medical countermeasures. bioRxiv. 2020;2020.05.06.081497.
   Google Scholar
• Ortiz-Alcantara JBK, Palaninathan S, Frieman M, Baric R, Kao C. Small molecule inhibitors of the SARS-CoV Nsp15 endoribonuclease. Virus Adapt Treat. 2010;2:125–133.
   Google Scholar
• Chandra A, Gurjar V, Qamar I, Singh N. Identification of potential inhibitors of SARS-COV-2 endoribonuclease (EndoU) from FDA approved drugs: a drug repurposing approach to find therapeutics for COVID-19. J Biomol Struct Dyn. 2020;1–11.
   Web of Science ®Google Scholar